Skip to main content

How does Nucala (mepolizumab) work? What is the MOA?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on Aug 12, 2025.

Official Answer by Drugs.com

Nucala (mepolizumab) is a monoclonal antibody that reduces inflammation by targeting eosinophils, a type of white blood cell. Excess eosinophils can contribute to inflammation, leading to conditions such as severe eosinophilic asthma and hypereosinophilic syndrome. Nucala belongs to a drug class known as interleukin-5 (IL-5) antagonists.

FDA-Approved Indications

Nucala (mepolizumab) is a targeted biologic therapy designed to treat several eosinophil-driven inflammatory conditions. Its use is supported by strong clinical trial data and regulatory reviews, resulting in FDA approval for specific patient groups with asthma, nasal polyps, EGPA (eosinophilic granulomatosis with polyangiitis), hypereosinophilic syndrome (HES), and, most recently, COPD with elevated eosinophil counts.

Condition Age Group Approval Year Notes
Severe eosinophilic asthma 6+ 2015 (adults); 2019 (ages 6-11) Add-on therapy, not for acute relief
Chronic rhinosinusitis with nasal polyps 18+ 2021 Add-on maintenance treatment
Eosinophilic granulomatosis with polyangiitis (EGPA) Adults 2017 Orphan indication, 300mg dose
Hypereosinophilic syndrome (HES) 12+ 2020 Must be ≥6 months without secondary cause
Chronic obstructive pulmonary disease (COPD, "smoker's lung") Adults 2025 For high eosinophil counts; add-on only

Nucala is not indicated for the relief of acute bronchospasm or status asthmaticus. Always use rescue medication for asthma attacks.

Related questions

Mechanism of Action (MOA)

Nucala works by blocking interleukin-5 (IL-5), a cytokine responsible for the growth, activation, and survival of eosinophils. By inhibiting IL-5, Nucala lowers eosinophil levels in the body, helping to reduce inflammation and manage symptoms of eosinophil-related diseases.

How Is Nucala Administered?

Nucala is given as a subcutaneous (under-the-skin) injection once every four weeks. It is administered as single (100mg) or triple (300mg) injections, depending on condition. The medication comes as prefilled syringes and autoinjectors.

Where to inject:

Inject Nucala into the thigh, abdomen, or upper arm (if a caregiver is present). Rotate injection sites—never inject into tender, damaged, or scarred skin.

Always follow your healthcare provider’s instructions for safe and effective use. For complete prescribing information, consult your doctor or review the official medication guide.

References
  1. Nucala [package insert]. Revised March 2023. GlaxoSmithKline LLC. Accessed 05/29/2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fefb887c-e4ac-431e-8893-e9d1a5a63fea

Read next

Can Nucala be self-administered? How is it injected?

Yes, Nucala can be self-administered. Nucala is available as a prefilled syringe or autoinjector that can be self-administered after a doctor has shown you how to administer it. 99% of people can successfully self-administer the Nucala prefilled syringe and 89-95% can successfully administer the Nucala autoinjector.

Continue reading

What is Nucala (mepolizumab) used for and how is it given?

Nucala (mepolizumab) is a biologic therapy used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). It is given by subcutaneous injection every four weeks. Continue reading

Can severe asthma lead to COPD?

Severe and poorly controlled asthma can lead to damaged lungs which may increase the risk of developing chronic obstructive pulmonary disease (COPD). Symptoms of asthma and COPD may frequently co-exist in smokers and the elderly. Continue reading

See also:

Related medical questions

Drug information

Related support groups